Ceribell Launches First FDA-Cleared AI-Powered Delirium Monitoring System

Ceribell, Inc. has commercially launched its artificial intelligence (AI)-powered delirium monitoring solution on its point-of-care brain monitoring platform. 

The technology combines seizure detection and delirium monitoring using a single system and headband, providing continuous electroencephalography (EEG)-based brain activity analysis in critical care settings.

The system uses proprietary AI algorithms to analyse EEG segments and identify patterns associated with delirium. 

It provides clinicians with alerts and neurological trends to support timely screening and continuous patient monitoring alongside conventional bedside clinical assessments. 

The platform is designed to help identify delirium, including its hypoactive form, which can be difficult to recognise through intermittent clinical evaluations.

The technology also enables clinicians to monitor non-convulsive seizures, which can present symptoms similar to hypoactive delirium. 

Its combined monitoring capabilities operate on the same hardware, reducing the need for separate monitoring equipment.

The commercial launch follows a successful pilot programme across multiple hospitals. The US Centers for Medicare & Medicaid Services (CMS) has also granted a New Technology Add-on Payment (NTAP) of up to US$2,171 per eligible Medicare patient case, effective 1 October 2026, subject to payment criteria.

The Ceribell Delirium Monitor received FDA 510(k) clearance in December 2025 for aiding delirium screening and monitoring in adult critical care patients.